Adenovirus Gene Transfer Vectors Inhibit Growth of Lymphatic Tumor Metastases Independent of a Therapeutic Transgene
- 1 September 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 12 (13) , 1639-1649
- https://doi.org/10.1089/10430340152528138
Abstract
Adenovirus (Ad) gene transfer vectors traffic to regional lymph nodes (RLNs) after footpad injections in mice, resulting in localized production of interferon γ (IFN-γ). With this background, we evaluated the hypothesis that Ad vector administration may inhibit RLN tumor metastasis independent of the transgene in the expression cassette. Tumors of MM48, a cell line with a propensity toward lymphogenous metastasis, were established in the footpads of syngeneic C3H mice, and E1-E3- Ad vectors encoding no transgene (AdNull) or encoding an irrelevant transgene (AdCD; Escherichia coli cytosine deaminase with no 5-fluorocytosine administration) were administered (1010 particles) in a peritumoral location. Both vectors suppressed the growth of tumor in the regional (popliteal) lymph node. This effect was localized to the regional, but not distant, lymph nodes (p < 0.05). Heat inactivation of the vector or decreasing the dose of the vector to 109 particles did not suppress RLN growth of the tumor when compared with 1010 particles of active AdNull (p < 0.05 and p < 0.01, respectively). The ability of an E1-E4- vector expressing β-galactosidase (AdRSVβgal.11) to suppress RLN tumor growth showed that the E4 region of the Ad vector was not responsible for the effect. Blocking either IFN-γ or natural killer (NK) cells with systemic antibody treatment in immunocompetent mice allowed rapid growth of RLN metastases despite Ad vector administration, and Ad vector injection into the footpads of tumor-free mice induced the accumulation of NK cells in the RLN. These data demonstrate that, in a metastatic murine tumor model, a low dose (1010 particles) of replication-deficient Ad vectors inhibits RLN metastases independent of a therapeutic transgene, an effect that is mediated, at least in part, by IFN-γ and NK cells.Keywords
This publication has 41 references indexed in Scilit:
- Adenovirus Vector-Mediated Gene Transfer to Regional Lymph NodesHuman Gene Therapy, 2000
- Gene therapy for cancerEuropean Journal Of Cancer, 1999
- Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacementGene Therapy, 1999
- Pharmacological expression in rat hepatocytes of a gene transferred by an adenovirus vector enabled by a chimeric promoter containing multiple cyclic adenosine monophosphate response elementsHepatology, 1998
- Cytotoxic T Lymphocyte Responses to Proteins Encoded by Heterologous Transgenes TransferredIn Vivoby Adenoviral VectorsHuman Gene Therapy, 1997
- Evidence for the Systemic Delivery of a Transgene Product from Salivary GlandsHuman Gene Therapy, 1996
- Regional Delivery of an Adenovirus Vector Containing the Escherichia coli Cytosine Deaminase Gene to Provide Local Activation of 5-Fluorocytosine to Suppress the Growth of Colon Carcinoma Metastatic to LiverHuman Gene Therapy, 1996
- In VivoAdenovirus-Mediated Gene Transfer of theEscherichia coliCytosine Deaminase Gene to Human Colon Carcinoma-Derived Tumors Induces Chemosensitivity to 5-FluorocytosineHuman Gene Therapy, 1995
- A case for cytokines as effector molecules in the resolution of virus infectionImmunology Today, 1993
- In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epitheliumCell, 1992